ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 12-Month High – Should You Buy?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) hit a new 52-week high during trading on Wednesday . The stock traded as high as $70.06 and last traded at $70.09, with a volume of 39352 shares. The stock had previously closed at $69.55.

Analyst Ratings Changes

Several equities analysts have issued reports on ANIP shares. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Guggenheim reaffirmed a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target for the company. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Price Performance

The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -125.84 and a beta of 0.49. The stock’s fifty day moving average price is $63.07 and its 200-day moving average price is $59.36. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Insider Activity

In other news, VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now owns 68,624 shares of the company’s stock, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $197,792 in the last quarter. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after acquiring an additional 340,854 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in ANI Pharmaceuticals by 14.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 1,972 shares during the period. Geode Capital Management LLC lifted its position in shares of ANI Pharmaceuticals by 4.2% during the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after purchasing an additional 17,314 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 691 shares during the period. Finally, Barclays PLC grew its holdings in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after purchasing an additional 135,003 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.